WHAT IS PCR?
PCR, short for Polymerase Chain Reaction, is a lab technique that quickly identifies infection causing organisms. Small quantities of DNA or RNA in a sample are amplified, and detected using a targeted approach for finding the pathogens (fungal, bacterial, viral, or parasitic).
Ipsum Diagnostic’s PCR technique more accurately and rapidly identifies potential pathogenic organisms and possible resistant genes than conventional culture methods. We can now identify the infection with greater sensitivity and specificity and recommend the medication that is most effective decreasing cost and morbidity.
Ipsum’s pathogen assay uses the latest PCR technology to reliably analyze your patients sample.
Our Dermatologic Panels
Post-Op/Acute Wound Panel
Extended Derm Panel
Antibiotic Resistance Genes
DERMATOLOGIC POLYMERASE CHAIN REACTION (PCR)
Why wait days for a bacterial panel and weeks for fungal culture results?
Ipsum Diagnostics can have your test results to you in less than 48 hours.
Real-time PCR utilizes highly specific assays for rapid, accurate profiling of polymicrobial infections. Let Ipsum provide your practice with quicker turn-around time for more effective treatment and superior patient care.
The advantages of PCR over traditional culture is unambiguous results that assist you with making all-important treatment decisions:
COMING SOON: Onychomycosis, Deep Fungal and Rate/Tropical Disease Panels
CONFIDENCE IN YOUR RESULTS
Ipsum’s unique pathogen target selection process and reporting process is provided by:
Like our dermatology pathogen selection process, ABR gene selection and interpretation is provided by highly trained and experienced infectious disease and dermatology physicians to Ipsum’s clients.
Criteria for ABR gene selection:
1. The gene is prevalent in pathogens commonly found associated with skin infections seen in US based dermatology practices (i.e., no need for genes found only in rare nosocomial pathogens reported in institutions outside the US)
2. The gene confers resistance to antibiotics typically used by office-based dermatologists in the US (i.e., no need for aminoglycoside resistance targets)
3. The presence or absence of the gene impacts the clinician’s antibiotic choice and duration of therapy (i.e., no need for genes associated with virulence factors such as P-V leukocidin or genes important for hospital epidemiology but not clinical practice)
4. Validation data including sensitivity, specificity, and predictive values compared to conventional culture-based tests are available for the individual assays
Disclaimer and Limitations
This test was developed and its performance characteristics were determined by Ipsum Diagnostics LLC. The test has not been cleared or approved by the U.S. Food & Drug Administration. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1998 (CLIA) as qualified to perform high complexity clinical laboratory testing.
The assay is designed to detect pathogenic and non-pathogenic organisms as well as antibiotic resistance genes found in soft-skin and tissue wounds. Qualitative real-time polymerase chain reaction is used to detect the presence or absence of organisms and antibiotic resistance genes. The panel only tests for the specific organisms and antibiotic resistance genes included in the panel. The panel is limited to those specific organisms and antibiotic resistance genes. The presence of any organism or antibiotic resistance gene not included in the panel cannot be excluded. Antibiotic resistance genes may be expressed by more than one organism, including organisms not included in the panel.
The information contained in this test report is intended to be interpreted by a licensed healthcare professional to determine its clinical significance. A positive result does not rule out infection or co-infection with other bacteria, fungi, or viruses not tested by the panel.
The listing of medications is for informational purposes only and is not intended or recommended as a substitute for medical advice, diagnosis, or treatment. The listing of medications does not imply the presence or severity of infection, or the need for treatment. Predicted susceptibility is specific to the organism(s) and/or antibiotic resistance gene(s) detected. Medications are based on standards, studies, guidelines, and reference material and are not created or developed by Ipsum Diagnostics LLC or any of its affiliates. All treatment decisions are the sole responsibility of the ordering physician or other qualified healthcare professional within the clinical context. Referral to an Infectious Disease Specialist may be indicated and is at the sole discretion of the ordering healthcare provider.